Up to 60% of men with classic Fabry disease have cardiac abnormalities, including left ventricular hypertrophy, valvular dysfunction, and conduction abnormalities. Recent data suggest that left ventricular hypertrophy and systolic function improve after 12 months of ERT.1 Systolic function is usually preserved, but mild to moderate impairment of diastolic filling is a relatively common finding, representing probably the most important cause of dyspnea in patients with Fabry disease.2
Blum A, Podovitzky O, Nuri J, Khasin M. Evaluating Enzyme Replacement Therapy in Fabry Disease—Reply. Arch Intern Med. 2010;170(6):573–574. doi:10.1001/archinternmed.2010.43
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: